{"id":585,"date":"2024-06-13T05:03:03","date_gmt":"2024-06-13T05:03:03","guid":{"rendered":"https:\/\/www.neolyspharma.ca\/nouvelles\/obtention-dun-financement-du-programme-elevation-de-mitacs-pour-soutenir-de-nouveaux-travaux-sur-les-derives-aminosteroides\/"},"modified":"2026-08-01T18:00:44","modified_gmt":"2026-08-01T18:00:44","slug":"mitacs-elevation-funding-aminosteroid-derivatives","status":"publish","type":"nouvelles","link":"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/","title":{"rendered":"Obtained funding from the MITACS ELEVATION programme to support new work on aminosteroid derivatives."},"content":{"rendered":"<p>Neolys Pharma has secured funding from the Mitacs Elevation programme to support new work on aminosteroid derivatives.<\/p>\n<p>Elevation funds postdoctoral research fellowships carried out in partnership between a company and an academic institution. The funding allows Neolys Pharma to continue characterizing its family of compounds, including RM-581, its most advanced candidate.<\/p>\n<p>The partnership continues work started in an academic setting on aminosteroid derivatives. It strengthens the link between fundamental research and the development of the company\u2019s portfolio.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"categories":[],"class_list":["post-585","nouvelles","type-nouvelles","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MITACS Elevation Funding | Neolys Pharma<\/title>\n<meta name=\"description\" content=\"Neolys Pharma secures funding from the MITACS Elevation programme to support new work on the aminosteroid derivatives.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MITACS Elevation Funding | Neolys Pharma\" \/>\n<meta property=\"og:description\" content=\"Neolys Pharma secures funding from the MITACS Elevation programme to support new work on the aminosteroid derivatives.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/\" \/>\n<meta property=\"og:site_name\" content=\"Neolyspharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-01T18:00:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/mitacs-elevation-funding-aminosteroid-derivatives\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/mitacs-elevation-funding-aminosteroid-derivatives\\\/\",\"name\":\"MITACS Elevation Funding | Neolys Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\"},\"datePublished\":\"2024-06-13T05:03:03+00:00\",\"dateModified\":\"2026-08-01T18:00:44+00:00\",\"description\":\"Neolys Pharma secures funding from the MITACS Elevation programme to support new work on the aminosteroid derivatives.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/mitacs-elevation-funding-aminosteroid-derivatives\\\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/mitacs-elevation-funding-aminosteroid-derivatives\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/mitacs-elevation-funding-aminosteroid-derivatives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Obtained funding from the MITACS ELEVATION programme to support new work on aminosteroid derivatives.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"name\":\"Neolys Pharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\"},\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\",\"name\":\"Neolys Pharma inc.\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"contentUrl\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"width\":512,\"height\":242,\"caption\":\"Neolys Pharma inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neolys-pharma\"],\"legalName\":\"Neolys Pharma inc.\",\"telephone\":\"+1-418-931-2195\",\"email\":\"info@neolyspharma.ca\",\"description\":\"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MITACS Elevation Funding | Neolys Pharma","description":"Neolys Pharma secures funding from the MITACS Elevation programme to support new work on the aminosteroid derivatives.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/","og_locale":"en_US","og_type":"article","og_title":"MITACS Elevation Funding | Neolys Pharma","og_description":"Neolys Pharma secures funding from the MITACS Elevation programme to support new work on the aminosteroid derivatives.","og_url":"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/","og_site_name":"Neolyspharma","article_modified_time":"2026-08-01T18:00:44+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/","url":"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/","name":"MITACS Elevation Funding | Neolys Pharma","isPartOf":{"@id":"https:\/\/neolyspharma.ca\/en\/#website"},"datePublished":"2024-06-13T05:03:03+00:00","dateModified":"2026-08-01T18:00:44+00:00","description":"Neolys Pharma secures funding from the MITACS Elevation programme to support new work on the aminosteroid derivatives.","breadcrumb":{"@id":"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neolyspharma.ca\/en\/news\/mitacs-elevation-funding-aminosteroid-derivatives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neolyspharma.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Obtained funding from the MITACS ELEVATION programme to support new work on aminosteroid derivatives."}]},{"@type":"WebSite","@id":"https:\/\/neolyspharma.ca\/en\/#website","url":"https:\/\/neolyspharma.ca\/en\/","name":"Neolys Pharma","description":"","publisher":{"@id":"https:\/\/neolyspharma.ca\/en\/#organization"},"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/neolyspharma.ca\/en\/#organization","name":"Neolys Pharma inc.","url":"https:\/\/neolyspharma.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","contentUrl":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","width":512,"height":242,"caption":"Neolys Pharma inc."},"image":{"@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neolys-pharma"],"legalName":"Neolys Pharma inc.","telephone":"+1-418-931-2195","email":"info@neolyspharma.ca","description":"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers."}]}},"_links":{"self":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/nouvelles\/585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/nouvelles"}],"about":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/types\/nouvelles"}],"wp:attachment":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/media?parent=585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/categories?post=585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}